Q-omics provides the consensus-scored DPY19L2P5 profile across patient tissues and cancer cell-line models. DPY19L2P5 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DPY19L2P5 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, DPY19L2P5 RNA expression shows 6,594 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, UCEC, and STAD as cancer lineages where DPY19L2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPY19L2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPY19L2P5 survival associations across molecular data types. DPY19L2P5 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPY19L2P5 RNA expression–survival associations across cancer types. High DPY19L2P5 expression shows unfavorable associations in THCA, THYM, LUSC and GBM, but favorable associations in KIRP and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify KIRP as the clearest survival context for DPY19L2P5 RNA expression.
This table summarizes DPY19L2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPY19L2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPY19L2P5 shows lower tumor expression in UCEC, THCA, LUSC and KICH and higher tumor expression in BRCA. The UCEC box plot shows higher DPY19L2P5 RNA expression in normal versus tumor tissue (log2 FC = −0.204, t-test p = .027).
This table shows molecular features associated with DPY19L2P5 in patient tissues and cancer cell lines. In patient samples, DPY19L2P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
